Navigation Links
Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
Date:5/8/2008

asis continues to be focused around 'Choice', the ability for Volcano to provide a number of different therapy enabling modalities, and letting the physician choose which technology is appropriate for each individual patient."

Christopher E. Banas, Vice President and General Manager of Volcano's OCT Division in San Antonio Texas, and former CEO and Chairman of CardioSpectra commented, "This is an important step in demonstrating the ability of Volcano's OCT catheter to safely image coronary vessels of human patients and establishing a leadership position in advanced coronary imaging technologies."

Volcano's OCT imaging platform provides high-resolution images in the 10- 15 micron range, opening the door for new applications to complement both IVUS and angiography. Michel Lussier, president of Volcano Europe commented, "The high resolution OCT images provide a glimpse at structural detail not seen before by other imaging modalities. We believe that OCT has the potential to identify thin-cap fibro-atheromas, clearly highlight intraluminal thrombus, and assess the complete healing of novel drug-eluting stent designs. Volcano is committed to exploring the various clinical benefits of our OCT platform through detailed data-driven study design and mutually beneficial partnerships with other therapy companies."

Patrick Serruys, M.D., commented, "The Volcano OCT Imaging Catheter is another step closer to delivering interventionalists with the true cath lab of the future. To better serve my patients, I want the flexibility to select from an array of different tools, quickly interrogate the vessel, and immediately process the information. Having these various technologies, including IVUS, OCT and FFR, all integrated into the lab, with a common user interface, review points, data storage and staff training provides this flexibility."

About Volcano Corporation

Volcano Corporation (NASDAQ:

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Earlier this month, a report was created ... U.S. Air Force on the performance of vehicles using ... type of fuel made from mustard seeds, offered great ... America’s Eco friendly future. In fact, every branch of ... independent of foreign oil over the next few years. ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:8/29/2014)... shifts over the last 120,000 years may have ... of researchers led by City College of New ... biodiversity metric called "phylogeographic endemism." , It quantifies ... species is restricted in geographical space. , Dr. ... other researchers from institutions in Brazil, Australia and ...
(Date:8/29/2014)... cell,s nucleus, chromosomal DNA is tightly bound to ... call chromatin. Until about two decades ago, histones ... packing material around which the glamorous DNA strands ... greater appreciation for how DNA/histone interactions govern gene ... institutions studying the sequence of the genome from ...
(Date:8/28/2014)... handful of bacterial culprits that may drive inflammatory bowel ... using patients, own intestinal immune responses as a guide. ... journal Cell . , Trillions of bacteria exist ... role in the development and progression of IBD. Yet ... species affect a person,s susceptibility to IBD and its ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Yale study identifies possible bacterial drivers of IBD 2
... New York University School of Medicine researchers provide some ... to air pollution--even at levels within federal standards--causes heart ... disease but until now it was poorly understood how ... well-designed mouse study, where animals breathed air as polluted ...
... diseases during in vitro fertilization offers couples the best ... could potentially cause doctors to misdiagnose a small fraction ... Citing concerns about the accuracy of preimplantation genetic diagnosis, ... embryos during IVF, UF researchers set out to study ...
... health hazard, researchers at the University of Rochester Medical Center ... in mice to harm the function of T-cells, which regulate ... , The discovery adds insight to the latest trend in ... public health threat to understanding the long-term burden on the ...
Cached Biology News:Researchers show how air pollution can cause heart disease 2Researchers show how air pollution can cause heart disease 3Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3The dangerous legacy of lead 2
pETDuet-1 is designed for the coexpression of two target genes....
... Recognizes K+ Cl- ... shows no significant sequence ... or CCC.,SPECIES REACTIVITIES: The ... conserved in human, mouse, ...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
oligophrenin-1 (H-100)...
Biology Products: